These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 19064014

  • 1. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.
    Roy P, Bonello L, Torguson R, de Labriolle A, Lemesle G, Slottow TL, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waksman R.
    Am J Cardiol; 2008 Dec 15; 102(12):1614-7. PubMed ID: 19064014
    [Abstract] [Full Text] [Related]

  • 2. Definition, incidence, correlates, and clinical impact of "nuisance" bleeding in patients undergoing drug-eluting stent implantation.
    Waksman R.
    Am J Cardiol; 2009 Sep 07; 104(5 Suppl):30C-3C. PubMed ID: 19695358
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, Guo YH, Cheng WJ, Jia de A, Cao Z, Nie B, Ge HL, Yang SW, Yan ZX.
    Thromb Res; 2009 May 07; 124(1):46-51. PubMed ID: 19041120
    [Abstract] [Full Text] [Related]

  • 5. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation.
    Ferreira-González I, Marsal JR, Ribera A, Permanyer-Miralda G, García-Del Blanco B, Martí G, Cascant P, Martín-Yuste V, Brugaletta S, Sabaté M, Alfonso F, Capote ML, De La Torre JM, Ruíz-Lera M, Sanmiguel D, Cárdenas M, Pujol B, Baz JA, Iñiguez A, Trillo R, González-Béjar O, Casanova J, Sánchez-Gila J, García-Dorado D.
    Circulation; 2010 Sep 07; 122(10):1017-25. PubMed ID: 20733100
    [Abstract] [Full Text] [Related]

  • 6. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ, CREDO Investigators.
    Am Heart J; 2009 Feb 07; 157(2):369-74. PubMed ID: 19185647
    [Abstract] [Full Text] [Related]

  • 7. A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.
    Han YL, Wang B, Li Y, Xu K, Wang SL, Jing QM, Wang ZL, Wang DM, Ma YY, Wang G.
    Chin Med J (Engl); 2009 Apr 05; 122(7):793-7. PubMed ID: 19493391
    [Abstract] [Full Text] [Related]

  • 8. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D, Kolman L, DeCaro M, Andrel J, Chervoneva I, Duong P, Lam L, McGowan C, Lee G, DeCaro M, Ruggiero N, Singhal S, Greenspon A.
    Pharmacotherapy; 2007 May 05; 27(5):691-6. PubMed ID: 17461704
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G, Rossini R, Lettieri C, Capodanno D, Romano M, Rosiello R, Guagliumi G, Valsecchi O, Gavazzi A, Angiolillo DJ.
    Catheter Cardiovasc Interv; 2012 Sep 01; 80(3):395-405. PubMed ID: 22109961
    [Abstract] [Full Text] [Related]

  • 12. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
    Khurram Z, Chou E, Minutello R, Bergman G, Parikh M, Naidu S, Wong SC, Hong MK.
    J Invasive Cardiol; 2006 Apr 01; 18(4):162-4. PubMed ID: 16729401
    [Abstract] [Full Text] [Related]

  • 13. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
    Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, Sirbu V, Bass TA, Della Rovere F, Gavazzi A, Angiolillo DJ.
    Am J Cardiol; 2008 Dec 15; 102(12):1618-23. PubMed ID: 19064015
    [Abstract] [Full Text] [Related]

  • 14. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
    Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, Gibson CM, TIMI Study Group.
    Am Heart J; 2009 Sep 15; 158(3):e21-6. PubMed ID: 19699846
    [Abstract] [Full Text] [Related]

  • 15. Observance of antiplatelet therapy after stent implantation in patients under chronic oral anticoagulant treatment.
    Valencia J, Mainar V, Bordes P, Pineda J, Gómez S, Sogorb F.
    J Interv Cardiol; 2008 Jun 15; 21(3):218-24. PubMed ID: 18422520
    [Abstract] [Full Text] [Related]

  • 16. Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation.
    Latib A, Morici N, Cosgrave J, Airoldi F, Godino C, Brambilla N, Chieffo A, Bonizzoni E, Carlino M, Bedogni F, Montorfano M, Sangiorgi GM, Briguori C, Colombo A.
    Am J Cardiol; 2008 Dec 01; 102(11):1477-81. PubMed ID: 19026299
    [Abstract] [Full Text] [Related]

  • 17. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents.
    Ben-Dor I, Torguson R, Scheinowitz M, Li Y, Delhaye C, Wakabayashi K, Maluenda G, Syed AI, Collins SD, Gonzalez MA, Gaglia MA, Xue Z, Kaneshige K, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.
    Am Heart J; 2010 May 01; 159(5):871-5. PubMed ID: 20435198
    [Abstract] [Full Text] [Related]

  • 18. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N.
    J Am Coll Cardiol; 2009 Mar 10; 53(10):849-56. PubMed ID: 19264241
    [Abstract] [Full Text] [Related]

  • 19. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT, Regal RE, Dorsch MP.
    Ann Pharmacother; 2008 Apr 10; 42(4):550-7. PubMed ID: 18319394
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ, CREDO Investigators.
    Am Heart J; 2008 Apr 10; 155(4):687-93. PubMed ID: 18371477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.